Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia

Clinical Cancer Research

Volumn 18, Issue 14, 2012, Pages 3812-3821

  Vitale, Laura A ^a   He, Li Zhen ^a   Thomas, Lawrence J ^a   Widger, Jennifer ^a   Weidlick, Jeffrey ^a   Crocker, Andrea ^a   O'Neill, Thomas ^a   Storey, James ^a   Glennie, Martin J ^b   Grote, Deanna M ^c   Ansell, Stephen M ^c   Marsh, Henry ^a   Keler, Tibor ^a  

^a Celldex Therapeutics Inc   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CDX 1127; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1F5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; LEUKEMIA; LIGAND BINDING; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; LYMPHOMA; LYMPHOMA CELL; MACACA; MALE; MOUSE; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD27; CELL PROLIFERATION; HUMANS; LEUKEMIA; LYMPHOMA; MICE; MICE, INBRED BALB C; MICE, SCID; MICE, TRANSGENIC; NEOPLASMS; T-LYMPHOCYTES;

EID: 84863918915     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3308     Document Type: Article

References (29)

1. Boyle EM, Morschhauser F. Ongoing development of monoclonal antibodies and antibody drug-conjugates in lymphoma. Curr Oncol Rep 2011;13;386-97.
2. Mayes S, Brown N, Illidge TM. New antibody drug treatments for lymphoma. Expert Opin Biol Ther 2011;11:623-40.
3. Hintzen RQ, Lens SM, Koopman G, Pals ST, Spits H, van Lier RA.CD70 represents the human ligand for CD27. Int Immunol 1994;6:477-80. (Pubitemid 24087241)
4. Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood Bcells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998;188: 1679-89. (Pubitemid 28516113)
5. van Lier RA, Borst J, Vroom TM, Klein H, Van Mourik P, Zeijlemaker WP, et al. Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. J Immunol 1987;139:1589-96. (Pubitemid 17141574)
6. de Jong R, Loenen WA, Brouwer M, van Emmerik L, de Vries EF, Borst J, et al. Regulation of expression of CD27, a T cell-specific member of a novel family of membrane receptors. J Immunol 1991;146:2488-94.
7. Xiao Y, Hendriks J, Langerak P, Jacobs H, Borst J. CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation. J Immunol 2004;172:7432-41. (Pubitemid 38747605)
8. Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, Borst J. CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 2000;1:433-40.
9. Hendriks J, Xiao Y, Borst J. CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. J Exp Med 2003;198:1369-80. (Pubitemid 37392482)
10. De Colvenaer V, Taveirne S, Delforche M, De Smedt M, Vandekerckhove B, Taghon T, et al. CD27-deficient mice show normal NK-cell differentiation but impaired function upon stimulation. Immunol Cell Biol 2011;89:803-11.
11. French RR, Taraban VY, Crowther GR, Rowley TF, Gray JC, Johnson PW, et al. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 2007;109:4810-5. (Pubitemid 46827776)
12. Keller AM, Schildknecht A, Xiao Y, van den Broek M, Borst J. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity. Immunity 2008;29:934-46.
13. Roberts DJ, Franklin NA, Kingeter LM, Yagita H, Tutt AL, Glennie MJ, et al. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J Immunother 2010;33:769-79.
14. Sakanishi T, Yagita H. Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice. Biochem Biophys Res Commun 2010;393:829-35.
15. Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda K, Yagita H, et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 2002;3:83-90. (Pubitemid 34065622)
16. Douin-Echinard V, Bornes S, Rochaix P, Tilkin AF, Peron JM, Bonnet J, et al. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status. Cancer Gene Ther 2000;7:1543-56. (Pubitemid 32098765)
17. Glouchkova L, Ackermann B, Zibert A, Meisel R, Siepermann M, Janka-Schaub GE, et al. The CD70/CD27 pathway is critical for stimulation of an effective cytotoxic T cell response against B cell precursor acute lymphoblastic leukemia. J Immunol 2009;182:718-25.
18. van Oers MH, Pals ST, Evers LM, van der Schoot CE, Koopman G, Bonfrer JM, et al. Expression and release of CD27 in human B-cell malignancies. Blood 1993;82:3430-6. (Pubitemid 23356716)
19. Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 1995;85:3556-65.
20. Trentin L, Zambello R, Sancetta R, Facco M, Cerutti A, Perin A, et al. B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. Cancer Res 1997;57:4940-7. (Pubitemid 27469006)
21. Molica S, Vitelli G, Levato D, Crispino G, Dell'Olio M, Dattilo A, et al. CD27 in B-cell chronic lymphocytic leukemia. Cellular expression, serum release and correlation with other soluble molecules belonging to nerve growth factor receptors (NGFr) superfamily. Haematologica 1998;83:398-402. (Pubitemid 28299244)
22. Murase S, Saio M, Takenaka K, Shinoda J, Nishimura Y, Sakai N, et al. Increased levels of CSF soluble CD27 in patients with primary central nervous system lymphoma. Cancer Lett 1998;132:181-6. (Pubitemid 28535203)
23. Dong HY, Shahsafaei A, Dorfman DM. CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naive B cells. Leuk Lymphoma 2002;43:1855-8. (Pubitemid 34874022)
24. Shao H, Yuan CM, Xi L, Raffeld M, Morris JC, Janik JE, et al. Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma. Am J Clin Pathol 2010;133:592-601.
25. Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol 2008;20:450-9.
26. Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR, et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994;368: 856-9. (Pubitemid 24137750)
27. Hintzen RQ, Lens SM, Lammers K, Kuiper H, Beckmann MP, van Lier RA. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J Immunol 1995;154:2612-23.
28. Gravestein LA, Nieland JD, Kruisbeek AM, Borst J. Novel mAbs reveal potent co-stimulatory activity of murine CD27. Int Immunol 1995;7:551-7.
29. Rankin CT, Veri MC, Gorlatov S, Tuaillon N, Burke S, Huang L, et al. CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. Blood 2006;108: 2384-91. (Pubitemid 44497523)